BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 17108988)

  • 1. Drug discovery and development for neglected parasitic diseases.
    Renslo AR; McKerrow JH
    Nat Chem Biol; 2006 Dec; 2(12):701-10. PubMed ID: 17108988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethical issues in funding research and development of drugs for neglected tropical diseases.
    Oprea L; Braunack-Mayer A; Gericke CA
    J Med Ethics; 2009 May; 35(5):310-4. PubMed ID: 19407037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health Organization.
    Savioli L; Engels D; Daumerie D; Jannin J; Alvar J; Asiedu K; Gastellu-Etchegorry M; Simarro P; Mariotti SP
    PLoS Med; 2006 Jun; 3(6):e283. PubMed ID: 16789805
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

  • 6. Genomics, systems biology and drug development for infectious diseases.
    Sakata T; Winzeler EA
    Mol Biosyst; 2007 Dec; 3(12):841-8. PubMed ID: 18000561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filling the pipeline for neglected diseases: creation of a medicinal chemistry-centric international drug discovery institute [iDDi].
    Kozikowski AP; Reitz AB
    Drug Discov Today; 2008 Feb; 13(3-4):97-8. PubMed ID: 18275906
    [No Abstract]   [Full Text] [Related]  

  • 8. Designing drugs for parasitic diseases of the developing world.
    McKerrow JH
    PLoS Med; 2005 Aug; 2(8):e210. PubMed ID: 16120007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A view on antimicrobial resistance in developing countries and responsible risk factors.
    Byarugaba DK
    Int J Antimicrob Agents; 2004 Aug; 24(2):105-10. PubMed ID: 15288307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Inhibitors as Antiparasitic Drugs: Pharmacological, Biochemical and Molecular Perspectives.
    Mukherjee S; Mukherjee N; Gayen P; Roy P; Babu SP
    Curr Drug Metab; 2016; 17(10):937-970. PubMed ID: 27719626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing drugs for parasitic diseases.
    Andreopoulos S
    Science; 2003 Apr; 300(5618):430-1. PubMed ID: 12702858
    [No Abstract]   [Full Text] [Related]  

  • 12. Apicomplexa, trypanosoma and parasitic nematode protein kinases as antiparasitic therapeutic targets.
    Liotta F; Siekierka JJ
    Curr Opin Investig Drugs; 2010 Feb; 11(2):147-56. PubMed ID: 20112164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccines against tropical parasitic diseases.
    Da'dara AA; Harn DA
    Expert Rev Vaccines; 2005 Aug; 4(4):575-89. PubMed ID: 16117713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more.
    Hotez P
    Health Aff (Millwood); 2011 Jun; 30(6):1080-7. PubMed ID: 21653960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host-parasite relations and implications for control.
    Fenwick A
    Adv Parasitol; 2009; 68():247-61. PubMed ID: 19289197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities and challenges in antiparasitic drug discovery.
    Pink R; Hudson A; Mouriès MA; Bendig M
    Nat Rev Drug Discov; 2005 Sep; 4(9):727-40. PubMed ID: 16138106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tropical diseases: the burden and its implications.
    Bradley DJ
    Schweiz Med Wochenschr; 1997 Sep; 127(39):1592-7. PubMed ID: 9342805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opening opportunities for new drugs against neglected diseases.
    Costi MP; Taramelli D; González-Pacanowska D
    ChemMedChem; 2008 Mar; 3(3):371-3. PubMed ID: 18324713
    [No Abstract]   [Full Text] [Related]  

  • 20. A theoretical flaw in the advance market commitment idea.
    Sonderholm J
    J Med Ethics; 2010 Jun; 36(6):339-43. PubMed ID: 20530089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.